WallStSmart
BNTX

BioNTech SE

NASDAQ: BNTX · HEALTHCARE · BIOTECHNOLOGY

$101.57
-0.48% today

Updated 2026-04-29

Market cap
$25.69B
P/E ratio
—
P/S ratio
8.95x
EPS (TTM)
$-5.50
Dividend yield
—
52W range
$80 – $124
Volume
1.2M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

BioNTech SE (BNTX) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$101.57
Consensus
$133.00
+30.94%
2030 Target
$273.54
+169.31%
DCF
$174.59
+37.35% MoS
13 analysts:
3 Buy3 Hold0 Sell

Management guidance

BioNTech targets becoming a multi-product company by 2030 with 15 Phase 3 oncology programs by end of 2026. Company plans 7 late-stage clinical data readouts in 2026. No specific revenue targets provided, but management indicated 2026 will see continued COVID vaccine revenue decline offset by oncology pipeline advancement. 2026 revenue guidance implies €2.29B (-20.31% YoY), with recovery expected as oncology products advance through Phase 3.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$455.90
$5.7B Rev × 20x P/S
Base case (2030)
$273.54
$5.7B Rev × 12x P/S
Bear case (2030)
$182.36
$5.7B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2030 (E)
Revenue$3.8B$2.8B$2.8B$2.3B$2.5B$3.2B$5.7B
Revenue growth—-28.0%0.2%-20.3%11.2%24.8%32.4%
EPS$3.83$-2.81$-3.87$-3.53$-2.80$-1.20$4.20
P/S ratio———12.0x12.0x12.0x12.0x
Implied price———$109.42$118.53$155.01$273.54

Catalysts & risks

Growth catalysts
+ 15 Phase 3 oncology trial readouts by end of 2026, particularly pumitamig lung cancer and gotistobart (54% death risk reduction in squamous NSCLC)
+ Oncology product launches expected 2027-2028 from late-stage pipeline (immunomodulators, ADCs, mRNA candidates)
+ €17.2 billion cash reserve enables aggressive R&D spending and potential M&A to accelerate oncology portfolio
+ Founder spinout removes uncertainty by Q2 2026, allowing clear strategic focus on core oncology business
Key risks
- Founder departure (Ugur Sahin, Özlem Türeci) by mid-2026 creates leadership transition risk and uncertainty around retained talent
- COVID-19 vaccine revenue cliff: 2025 revenue €2.87B declining to €2.29B in 2026 (-20.31%), further declines likely 2027-2028
- Singapore manufacturing facility closure (Feb 2027) signals excess capacity and further restructuring costs ahead
- Oncology pipeline execution risk: no approved products yet; 15 Phase 3 trials represent high execution risk with potential for failures
- Analyst price targets reduced significantly: BMO cut from €143 to €128, Morgan Stanley cut to €125 on leadership concerns and conservative COVID guidance
- Shareholder litigation risk: Johnson Fistel investigating compliance with federal securities laws regarding guidance and founder departures

Methodology

BioNTech SE's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 13 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.